- Cambridge Rare Disease Network Festival #RAREfest22 – 25th-26th November 2022 RAREfest22 has patients at its heart with science and technology running through its veins! Cambridge Rare Disease Network’s festival is back in person showcasing expert speakers, live podcasts, panel discussions hands-on exhibits and film from the world of science, tech, and advocacy. Join us ...
- Today our lovely team completed the Challenge raising £1,473.16!! Read more about the team and Alan’s son Theo 8 here Thank you to everyone involved!!!
- September 2021 New rules mean if you live in England your can now DONATE PLASMA!! Plasma is needed to make immunoglobulin medicine that can be used to treat many conditions, saving many lives…. THANK YOU!!! Your plasma will help people with cancers, rare diseases, immune disorders and genetic conditions. Register online or call ...
- Rallybio Announces First-in-Human Dosing in RLYB211 Phase 1/2 Study. RLYB211 is in Clinical Development for the Prevention of FNAIT, a Potentially Life-Threatening Rare Disorder that Impacts Fetuses and Newborns. NEW HAVEN, Conn., November 10, 2020. Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and ...
- FREE to attend, RAREfest20 is a full day festival featuring interactive exhibits showcasing cool science, visionary technology and pioneering organisations, improving lives and bringing hope to those affected by rare diseases. In true 2020 style, RAREfest20 promises to be a virtual feast that will spark curiosity, challenge perceptions, showcase science, inspire innovation and give ...
- Severe thrombocytopenia leading to bleeding into major organs, including intracranial haemorrhage (ICH) can result in miscarriage, loss of the newborn or severe life-long neurological disability. The following animation explaining Fetal and neonatal alloimmune thrombocytopenia has been made by Rallybio, who are a clinical-stage biotechnology company who are in the process of developing a prophylactic ...